DeGregorio Family Foundation awards $87,500 to Howard University researcher to study immunotherapy in gastric cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The DeGregorio Family Foundation with the support of the Price Family Foundation and the Esophageal Cancer Awareness Association has awarded $87,500 to Dawit Kidane-Mulat, associate professor at Howard University College of Medicine, to complete his grant focused on improving the effectiveness of immunotherapy in gastric cancers.

The overarching goal of this study is to harness XRCC1-deficient gastroesophageal cancer cells that will likely enhance the efficacy of immunotherapy response. Kidane-Mulat is examining how defective XRCC1 and DNA damage response targeting contributes to aberrant innate immune cells’ inflammatory response.

This work lays the foundation for additional in-depth preclinical studies, and for the development of novel therapeutic strategies for stomach cancer.

“As a result of this award, I am generating a long line of research into understanding the basis of DNA repair/response and immunotherapy treatment in stomach cancer,” Kidane-Mulat said in a statement. “This grant award is opening a new opportunity to propel the field forward and build a solid foundation for future immunotherapy therapeutic strategies in gastric cancer.”

The DeGregorio Family Foundation has raised more than $8 million to fund innovative research focused on curing gastric and esophageal cancers.

Table of Contents

YOU MAY BE INTERESTED IN

NCI Director Kimryn Rathmell has released her professional judgment budget proposal, requesting nearly $11.5 billion—the same amount as last year’s proposal prepared by her predecessor, Monica Bertagnolli.
Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant. 

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login